Enbrel (Etanercept) and Biosimilar Market was valued at USD 8.5 Billion in 2022 and is projected to reach USD 14.2 Billion by 2030, growing at a CAGR of 8.4% from 2024 to 2030.
From 2018 to 2022, the Enbrel (Etanercept) and biosimilar market has witnessed dynamic shifts, driven by the increasing adoption of biosimilars, patent expirations, and pricing pressure. Enbrel, an injectable biologic, has long been used for treating conditions like rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. As patents expired, biosimilars such as Erelzi and Brenzys gained market entry, offering a more affordable alternative to the original drug.
Enbrel’s market presence remained strong through 2022, despite competition from these biosimilars. The uptake of biosimilars was more significant in Europe, where regulatory pathways for biosimilar approval are well-established. Meanwhile, the U.S. market saw slower adoption due to varying insurance reimbursements, complex regulatory challenges, and the familiarity of physicians and patients with Enbrel as a trusted treatment. The period from 2018 to 2022 also witnessed advancements in the production and availability of biosimilars, leading to growing acceptance in clinical practice.
Downlod Now
As we move into 2023 and beyond, the outlook for Enbrel and its biosimilars shifts significantly. From 2023 to 2033, it is projected that biosimilars will continue to dominate the Enbrel treatment space, with many more biosimilar products entering the market. By 2030, the global biosimilar market for Enbrel is expected to surpass the original drug’s market share, driven by increasing competition and reduced treatment costs. Cost containment measures by healthcare providers and insurers will further accelerate this shift. Biosimilars are forecast to capture significant portions of the rheumatoid arthritis market in regions like North America, where the biosimilar market is expected to expand dramatically after 2023.
The market for Enbrel, however, is not expected to diminish entirely. Enbrel will continue to hold a portion of the market due to physician loyalty, patient preferences, and perceived stability in treatment outcomes. Moreover, emerging markets such as Asia-Pacific, where Enbrel has less competition from biosimilars, will see steady demand for the original biologic. While biosimilars will see widespread adoption, Enbrel's brand will still maintain relevance, particularly in markets with regulatory delays or physician hesitations about biosimilar safety.
In summary, from 2018 to 2022, Enbrel’s market was characterized by steady growth despite the rise of biosimilars. However, from 2023 to 2033, biosimilars are poised to drive significant changes in market dynamics, offering cost-effective alternatives while maintaining some of Enbrel’s dominance in specific regions.
Get an In-Depth Research Analysis of the Global Enbrel (Etanercept) and Biosimilar Market Size And Forecast [2025-2032]
Pfizer
Amgen
Samsung Bioepis
Novartis
3s Bio
Lupin
By the year 2030, the scale for growth in the market research industry is reported to be above 120 billion which further indicates its projected compound annual growth rate (CAGR), of more than 5.8% from 2023 to 2030. There have also been disruptions in the industry due to advancements in machine learning, artificial intelligence and data analytics There is predictive analysis and real time information about consumers which such technologies provide to the companies enabling them to make better and precise decisions. The Asia-Pacific region is expected to be a key driver of growth, accounting for more than 35% of total revenue growth. In addition, new innovative techniques such as mobile surveys, social listening, and online panels, which emphasize speed, precision, and customization, are also transforming this particular sector.
Get Discount On The Purchase of the Global Enbrel (Etanercept) and Biosimilar Market Size And Forecast [2025-2032]
Growing demand for below applications around the world has had a direct impact on the growth of the Global Enbrel (Etanercept) and Biosimilar Market
Hospital
Pharmacy
Other
Based on Types the Market is categorized into Below types that held the largest Enbrel (Etanercept) and Biosimilar market share In 2023.
Syringe
Pen
Global (United States, Global and Mexico)
Europe (Germany, UK, France, Italy, Russia, Turkey, etc.)
Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
South America (Brazil, Argentina, Columbia, etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
For More Information or Query, Visit @ Enbrel (Etanercept) and Biosimilar Market Research Analysis
1. Introduction of the Global Enbrel (Etanercept) and Biosimilar Market
Overview of the Market
Scope of Report
Assumptions
2. Executive Summary
3. Research Methodology of Verified Market Reports
Data Mining
Validation
Primary Interviews
List of Data Sources
4. Global Enbrel (Etanercept) and Biosimilar Market Outlook
Overview
Market Dynamics
Drivers
Restraints
Opportunities
Porters Five Force Model
Value Chain Analysis
5. Global Enbrel (Etanercept) and Biosimilar Market, By Type
6. Global Enbrel (Etanercept) and Biosimilar Market, By Application
7. Global Enbrel (Etanercept) and Biosimilar Market, By Geography
Global
Europe
Asia Pacific
Rest of the World
8. Global Enbrel (Etanercept) and Biosimilar Market Competitive Landscape
Overview
Company Market Ranking
Key Development Strategies
9. Company Profiles
10. Appendix
About Us: Verified Market Reports
Verified Market Reports is a leading Global Research and Consulting firm servicing over 5000+ global clients. We provide advanced analytical research solutions while offering information-enriched research studies. We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.
Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
Contact us:
Mr. Edwyne Fernandes
US: +1 (650)-781-4080
US Toll-Free: +1 (800)-782-1768
Website: https://www.verifiedmarketreports.com/